Bis-diketopiperazine derivatives in clinical oncology

ICRF-159

D. S. Poster, J. Penta, S. Marsoni, S. Bruno, J. S. Macdonald

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

ICRF-159 is a bis-diketopiperazine derivative active in a variety of preclinical animal tumor models. Because of its poor solubility characteristics, the drug must be given p.o. However, when given by this route at high doses, poor bioavailability was noted. Two interesting preclinical properties of this agent are its antimetastatic effect and the ability to reduce anthracycline cardiotoxicity. Phase I studies have delineated myelosuppression as the major toxicity with GI toxicity also occurring. In phase II studies, interesting activity has been noted in lymphomas and head and neck carcinomas. When ICRF-159 was combined with radiotherapy, prolonged responses were noted in sarcoma and lung carcinoma in small numbers of patients. Further studies are indicated in areas of activity as a single agent and as a potentiator of radiation therapy.

Original languageEnglish
Pages (from-to)315-320
Number of pages6
JournalCancer Clinical Trials
Volume3
Issue number4
Publication statusPublished - 1980

Fingerprint

Razoxane
Diketopiperazines
Medical Oncology
Radiotherapy
Carcinoma
Anthracyclines
Sarcoma
Solubility
Biological Availability
Lymphoma
Neck
Animal Models
Head
Lung
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Poster, D. S., Penta, J., Marsoni, S., Bruno, S., & Macdonald, J. S. (1980). Bis-diketopiperazine derivatives in clinical oncology: ICRF-159. Cancer Clinical Trials, 3(4), 315-320.

Bis-diketopiperazine derivatives in clinical oncology : ICRF-159. / Poster, D. S.; Penta, J.; Marsoni, S.; Bruno, S.; Macdonald, J. S.

In: Cancer Clinical Trials, Vol. 3, No. 4, 1980, p. 315-320.

Research output: Contribution to journalArticle

Poster, DS, Penta, J, Marsoni, S, Bruno, S & Macdonald, JS 1980, 'Bis-diketopiperazine derivatives in clinical oncology: ICRF-159', Cancer Clinical Trials, vol. 3, no. 4, pp. 315-320.
Poster DS, Penta J, Marsoni S, Bruno S, Macdonald JS. Bis-diketopiperazine derivatives in clinical oncology: ICRF-159. Cancer Clinical Trials. 1980;3(4):315-320.
Poster, D. S. ; Penta, J. ; Marsoni, S. ; Bruno, S. ; Macdonald, J. S. / Bis-diketopiperazine derivatives in clinical oncology : ICRF-159. In: Cancer Clinical Trials. 1980 ; Vol. 3, No. 4. pp. 315-320.
@article{8e4770db2d3e4594bc9e07cfc3ffe1bc,
title = "Bis-diketopiperazine derivatives in clinical oncology: ICRF-159",
abstract = "ICRF-159 is a bis-diketopiperazine derivative active in a variety of preclinical animal tumor models. Because of its poor solubility characteristics, the drug must be given p.o. However, when given by this route at high doses, poor bioavailability was noted. Two interesting preclinical properties of this agent are its antimetastatic effect and the ability to reduce anthracycline cardiotoxicity. Phase I studies have delineated myelosuppression as the major toxicity with GI toxicity also occurring. In phase II studies, interesting activity has been noted in lymphomas and head and neck carcinomas. When ICRF-159 was combined with radiotherapy, prolonged responses were noted in sarcoma and lung carcinoma in small numbers of patients. Further studies are indicated in areas of activity as a single agent and as a potentiator of radiation therapy.",
author = "Poster, {D. S.} and J. Penta and S. Marsoni and S. Bruno and Macdonald, {J. S.}",
year = "1980",
language = "English",
volume = "3",
pages = "315--320",
journal = "Cancer Clinical Trials",
issn = "0190-1206",
publisher = "Masson Publishing",
number = "4",

}

TY - JOUR

T1 - Bis-diketopiperazine derivatives in clinical oncology

T2 - ICRF-159

AU - Poster, D. S.

AU - Penta, J.

AU - Marsoni, S.

AU - Bruno, S.

AU - Macdonald, J. S.

PY - 1980

Y1 - 1980

N2 - ICRF-159 is a bis-diketopiperazine derivative active in a variety of preclinical animal tumor models. Because of its poor solubility characteristics, the drug must be given p.o. However, when given by this route at high doses, poor bioavailability was noted. Two interesting preclinical properties of this agent are its antimetastatic effect and the ability to reduce anthracycline cardiotoxicity. Phase I studies have delineated myelosuppression as the major toxicity with GI toxicity also occurring. In phase II studies, interesting activity has been noted in lymphomas and head and neck carcinomas. When ICRF-159 was combined with radiotherapy, prolonged responses were noted in sarcoma and lung carcinoma in small numbers of patients. Further studies are indicated in areas of activity as a single agent and as a potentiator of radiation therapy.

AB - ICRF-159 is a bis-diketopiperazine derivative active in a variety of preclinical animal tumor models. Because of its poor solubility characteristics, the drug must be given p.o. However, when given by this route at high doses, poor bioavailability was noted. Two interesting preclinical properties of this agent are its antimetastatic effect and the ability to reduce anthracycline cardiotoxicity. Phase I studies have delineated myelosuppression as the major toxicity with GI toxicity also occurring. In phase II studies, interesting activity has been noted in lymphomas and head and neck carcinomas. When ICRF-159 was combined with radiotherapy, prolonged responses were noted in sarcoma and lung carcinoma in small numbers of patients. Further studies are indicated in areas of activity as a single agent and as a potentiator of radiation therapy.

UR - http://www.scopus.com/inward/record.url?scp=0019126718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019126718&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 315

EP - 320

JO - Cancer Clinical Trials

JF - Cancer Clinical Trials

SN - 0190-1206

IS - 4

ER -